Skip to main content
. 2021 Dec 20;45(1):45–64. doi: 10.1007/s40264-021-01127-2

Fig. 7.

Fig. 7

Any-grade treatment-emergent adverse events leading to treatment discontinuation in two or more patients in the RAM + ERL arm in RELAY. ERL erlotinib, PBO placebo, RAM ramucirumab